Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

doi:10.1136/rmdopen-2020-001323

. 2020 Oct;6(3):e001323.

doi: 10.1136/rmdopen-2020-001323.

Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

Serena Bugatti^{1

2}, Ludovico De Stefano^{3

2}, Francesca Bobbio-Pallavicini³, Carlomaurizio Montecucco^{3

2}

Affiliations

¹ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy serena.bugatti@unipv.it.
² Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
³ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

PMID: 33087414
PMCID: PMC7722363
DOI: 10.1136/rmdopen-2020-001323

Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

Serena Bugatti et al. RMD Open. 2020 Oct.

. 2020 Oct;6(3):e001323.

doi: 10.1136/rmdopen-2020-001323.

Authors

Serena Bugatti^{1

2}, Ludovico De Stefano^{3

2}, Francesca Bobbio-Pallavicini³, Carlomaurizio Montecucco^{3

2}

Affiliations

¹ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy serena.bugatti@unipv.it.
² Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
³ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

PMID: 33087414
PMCID: PMC7722363
DOI: 10.1136/rmdopen-2020-001323

No abstract available

Keywords: Arthritis; Hydroxychloroquine; Lupus Erythematosus; Rheumatoid; Systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Cited by

How Did Patients Living With Immune-Mediated Rheumatic Diseases Face the Beginning of the COVID-19 Pandemic in Brazil? Results of the COnVIDa Study.
Pugliesi A, Sachetto Z, de Medeiros Pinheiro M, Salviato Pileggi G, Sarot Pereira da Cunha G, Hajar FN, Marques Negrisolli Cunha ML, Henrique da Mota LM, Lopes Marques CD, Kakehasi AM, Rodrigues Ferreira WH, Araújo NC, Monteiro Gomides Reis AP, Rodrigues de Abreu Vieira RM, Ferreira GA, Danowski A, de Souza VA, Soares Egypto de Brito DC, Dos Santos Paiva E, Provenza JR, Feijó Azevedo V. Pugliesi A, et al. J Clin Rheumatol. 2024 Jan 1;30(1):e29-e33. doi: 10.1097/RHU.0000000000001882. Epub 2022 Jun 14. J Clin Rheumatol. 2024. PMID: 35699528 Free PMC article.
Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.
Selvarajan S, Anandaradje A, Shivabasappa S, Melepurakkal Sadanandan D, Nair NS, George M. Selvarajan S, et al. Br J Clin Pharmacol. 2022 Sep;88(9):4080-4091. doi: 10.1111/bcp.15338. Epub 2022 Apr 13. Br J Clin Pharmacol. 2022. PMID: 35357033 Free PMC article.

References

1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732–9. 10.1093/cid/ciaa237 - DOI - PMC - PubMed
1. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16 10.1038/s41421-020-0156-0 - DOI - PMC - PubMed
1. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66. 10.1038/s41584-020-0372-x - DOI - PubMed
1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect 2020;80:607–13. 10.1016/j.jinf.2020.03.037 - DOI - PMC - PubMed
1. Schreiber K, Breen K, Parmar K, et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology 2018;57:120–4. 10.1093/rheumatology/kex378 - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732–9. 10.1093/cid/ciaa237 - DOI - PMC - PubMed

[2] Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732–9. 10.1093/cid/ciaa237 - DOI - PMC - PubMed

[3] Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16 10.1038/s41421-020-0156-0 - DOI - PMC - PubMed

[4] Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16 10.1038/s41421-020-0156-0 - DOI - PMC - PubMed

[5] Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66. 10.1038/s41584-020-0372-x - DOI - PubMed

[6] Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66. 10.1038/s41584-020-0372-x - DOI - PubMed

[7] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect 2020;80:607–13. 10.1016/j.jinf.2020.03.037 - DOI - PMC - PubMed

[8] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect 2020;80:607–13. 10.1016/j.jinf.2020.03.037 - DOI - PMC - PubMed

[9] Schreiber K, Breen K, Parmar K, et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology 2018;57:120–4. 10.1093/rheumatology/kex378 - DOI - PubMed

[10] Schreiber K, Breen K, Parmar K, et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology 2018;57:120–4. 10.1093/rheumatology/kex378 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

Affiliations

Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous